Adagene Announces First Patients Dosed in Global Phase 1 Clinical Trial of ADG126, Lead SAFEbody™ Program

NEXT STORY
Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy
PREV STORY
Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Chemiluminescence Immunoassay Analyzers Market Research Report by Product, by End-User, by Application – Global Forecast to 2025 – Cumulative Impact of COVID-19

author_avatar
NASDAQ Market News

Predictive Oncology Announces Closing of $3.074 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

author_avatar
NASDAQ Market News

Shire plc : Notice of Results

author_avatar
NASDAQ Market News